IFIH1 and dermatomyositis: This potent immunosuppressive therapy consisted of high-dose glucocorticoids, an IVCY pulse, and oral calcineurin inhibitors, and was previously shown to improve the survival rate of anti-MDA5 Ab+ DM patients.[2] However, approximately 25% of anti-MDA5 Ab+ DM patients did not survive even with triple therapy.